AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $4.8M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$4.8M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 3 added, 3 cutEven
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $512.16
- 52-wk high
- $556.27
- High
- $514.50
- 52-wk low
- $364.23
- Low
- $503.36
- Prev close
- $512.05
- Mkt cap
- $6.69B
- P/E
- 25.8x
- Volume
- 155.9K
- Fwd P/E
- 18.2x
- Beta
- 0.51
- Div yield
- 0.47%
- P/S
- 2.6x
- P/B
- 7.8x
- Profit margin
- +10.6%
- Op margin
- +13.3%
- ROE
- +27.1%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about CHE filings
Are insiders buying or selling Chemed Corp (CHE) stock?
Net selling: insiders sold $4.8M and bought $0 of CHE stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. The largest was Mcnamara, Kevin J (president and CEO), who sold $4.2M. The latest filing was on Sep 30, 2026.
Which members of Congress have traded CHE recently?
None. No member of Congress disclosed a CHE trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this CHE smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (1)
- AQ
AQR
$289.2M
added
Sells/Trims (2)
- TS
Two Sigma
$103.5M
trimmed
- CI
Citadel
$43.1M
sold
What insiders are doing
How top traders are positioned
No tracked top-trader positions in CHE right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 7.8% above what analysts expected.
Earnings per share
$5.12 expected
Reports Oct 27, 2026, in 26 days
Estimates as of Sep 30, 2026
EPS expected
$6.31 to $6.54
Revenue expected
5 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $618.8M | $624.9M | $639.3M | $657.5M |
| Cost of what it sold | $434.1M | $444.2M | $433.3M | $458.6M |
| Gross profit | $184.7M | $180.7M | $206.0M | $198.9M |
| What it spent | ||||
| Sales and admin | $99.4M | $105.8M | $105.5M | $114.3M |
| Other operating costs | $17.2M | — | — | — |
| Total operating expenses | $116.6M | $105.8M | $105.5M | $114.3M |
| What was left | ||||
| Operating profit | $68.1M | $74.8M | $100.7M | $84.6M |
| Interest on debt | $443.0K | $2.0M | $521.0K | $512.0K |
| Profit before tax | $71.1M | $83.5M | $105.4M | $88.8M |
| Tax | $18.6M | $19.3M | $28.7M | $22.5M |
| Net profit | $52.5M | $64.2M | $76.8M | $66.3M |
| EBITDA | $87.8M | $101.8M | $122.3M | $106.2M |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bullish
CHE Initiates Coverage by UBS -- Price Target Announced at $650
BullishSep 25Chemed Corp (CHE) Stock Up 3.3% and Still Undervalued -- GF Scor
BullishSep 25UBS initiates Chemed stock coverage with buy rating on growth outlook
BullishSep 25UBS initiates Chemed stock coverage with buy rating on growth outlook
BullishSep 25Form 144 CHEMED CORP For: 24 September By Investing.com
NeutralSep 24Chemed (CHE) Buys a $60.6M Roto-Rooter Franchise. Can Ownership Lift Returns?
NeutralSep 22Chemed Insider Sold Shares Worth $1,002,800, According to a Recent SEC Filing
Leans bearishSep 22Chemed president and CEO Kevin McNamara sells $1.0m in company stock
Leans bearishSep 22
Macro
21 macro signals shaping CHE right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results